📰 Genentech News
Page 148 - Genentech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genentech. Real-time updates on events, politics, business and more.
June 8, 2023
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it is supporting...
June 8, 2023
Dermatological Remedies Overview and Analysis Get Free Sample Report: Dermatological Remedies Market Research Report 2023-2031Dermatological Remedies
June 7, 2023
/PRNewswire/ -- Emtrain, an eLearning and analytics technology company that develops and measures respect and inclusion in the workplace, today announced that...
June 7, 2023
Son of immigrant parents from India to be awarded University Medal as the top graduating senior on June 17
June 7, 2023
Rates of germline genetic testing for patients newly diagnosed with common cancers are far below recommended levels, prompting calls for innovative solutions.
June 7, 2023
In a recent Contemporary Clinical Trials commentary, University of Illinois Chicago researchers and colleagues explain how embedded pragmatic clinical trials, or ePCTs, which test the effectiveness of medical interventions in real-world settings, potentially leave out people who are from underrepresented and underserved groups.
June 6, 2023
CHICAGO — Adjuvant pembrolizumab showed durable benefit vs. placebo among patients with resected stage IIB or IIC melanoma, according to randomized phase 3 study results presented at ASCO Annual Meeting.After more than 3 years of follow-up, patients assigned the anti-PD-1 therapy achieved significantly longer distant metastasis-free survival (DMFS) and RFS, results of the KEYNOTE-716 trial
June 6, 2023
(This May 31 story has been corrected to fix the spelling of executive's name to Teresa, not Theresa, in paragraph 5) | 08:32pm
June 6, 2023
Second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplant in patients with early relapsed or refractory large B-cell lymphoma.
June 6, 2023
The combination of pembrolizumab plus axitinib continued to improve overall survival, progression-free survival, and overall response rate over sunitinib monotherapy in patients with treatment-naïve clear cell renal cell carcinoma.